JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrugresistance of hepatocellular carcinoma cells

Hepatobiliary and Pancreatic Diseases International

Volumn 9, Issue 3, 2010, Pages 287-295

  Yan, Feng ^a,b   Wang, Xiao Min ^a,b   Liu, Zhong Chen ^a,b   Pan, Chao ^a   Yuan, Si Bo ^a,b   Ma, Quan Ming ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

c Jun NH2 terminal kinase; Hepatocellular carcinoma; Multidrug resistance; Multidrug resistance associated protein; P glycoprotein

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 10; MITOGEN ACTIVATED PROTEIN KINASE 9; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IC50; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 10; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHOSPHORYLATION; RNA, MESSENGER; TIME FACTORS;

EID: 77953830891     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83.
2. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14: 1652-1656.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
4. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007;31:1465-1472.
5. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859-1876.
6. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 2008;20: 731-735.
7. Yan F, Jiang Y, Li YM, Zhen X, Cen J, Fang WR. Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetrataisohydroquinolin derivatives. Biol Pharm Bull 2008;31:1258-1264.
8. Stierlé V, Duca M, Halby L, Senamaud-Beaufort C, Capobianco ML, Laigle A, et al. Targeting MDR1 gene: synthesis and cellular study of modified daunomycin-triplexforming oligonucleotide conjugates able to inhibit gene expression in resistant cell lines. Mol Pharmacol 2008;73: 1568-1577.
9. Hu XF, Li J, Yang E, Vandervalk S, Xing PX. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007;96: 918-927.
10. Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006;66:445-452.
11. Lukyanova NY, Rusetskya NV, Tregubova NA, Chekhun VF. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009;31:87-91.
12. Li Y, Li S, Han Y, Liu J, Zhang J, Li F, et al. Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur J Pharmacol 2008;591:252-258.
13. Yan F, Wang XM, Pan C, Ma QM. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells. World J Gastroenterol 2009;15:1443-1451.
14. Yan F, Wang XM, Pan C. Expression of ERK5 in multidrugresistant hepatocellular carcinoma cell line. Nan Fang Yi Ke Da Xue Xue Bao 2009;29:483-486.
15. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2- terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057-9061.
16. Liu M, Li D, Aneja R, Joshi HC, Xie S, Zhang C, et al. PO(2)- dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem 2007;282:17581-17586.
17. Maruyama J, Naguro I, Takeda K, Ichijo H. Stress-activated MAP kinase cascades in cellular senescence. Curr Med Chem 2009;16:1229-1235.
18. Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003;63:4527-4532.
19. Kang CD, Ahn BK, Jeong CS, Kim KW, Lee HJ, Yoo SD, et al. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp Cell Res 2000;256:300-307.
20. Wartenberg M, Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, et al. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumorspheroids by reactive oxygen species. J Biol Chem 2001;276: 17420-17428.
21. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
22. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR. A 190-kilodalton protein overexpressed innon-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 1994;86: 110-117.
23. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer 1994;58:400-406.
24. Rebbaa A. Targeting senescence pathways to reverse drug resistance in cancer. Cancer Lett 2005;219:1-13.
25. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007;1775:5-20.
26. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-127.
27. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Dérijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760-2770.
28. Finch A, Davis W, Carter WG, Saklatvala J. Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo: activation of hepatic c-Jun N-terminal kinases 1 and 2, and mitogen-activated protein kinase kinases 4 and 7. Biochem J 2001;353:275-281.
29. Shibata W, Maeda S, Hikiba Y, Yanai A, Sakamoto K, Nakagawa H, et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res 2008;68:5031-5039.
30. Bjorkblom B, Vainio JC, Hongisto V, Herdegen T, Courtney MJ, Coffey ET. All JNKs can kill, but nuclear localization is critical for neuronal death. J Biol Chem 2008;283:19704-19713.